Stryker Corporation is seeing strong medical device sales and industry growth that has left its stock undervalued by 13% [1].
This valuation gap suggests a potential opportunity for investors as the broader medical technology sector expands through high-value transactions and increased demand for specialized devices.
The company previously raised its annual profit forecast on Thursday, Jan. 29, following a period of robust sales for its medical devices [2]. Market analysts said that the company is well-positioned for future gains due to a strong earnings per share growth outlook and potential for dividends [1].
"Stryker stock looks undervalued with a 13% discount to fair value, a strong EPS growth outlook, and dividend potential," Seeking Alpha said [1].
This growth occurs within a wider industry trend of massive corporate restructuring and acquisition. Analysis from EY in 2026 highlighted the scale of these shifts, noting that some of the largest transactions included Abbott's $21 billion acquisition of Exact Sciences [3].
Other significant movements in the sector include Becton Dickinson's $17.5 billion divestment of its Biosciences and Diagnostic division [3]. These multi-billion dollar shifts indicate a volatile but expanding market where companies are aggressively refining their portfolios to capture growth in specific medical niches.
Stryker's ability to maintain strong sales while trading below its fair value indicates a divergence between the company's operational success and its current market price [1]. The company continues to benefit from the global increase in medical device adoption and the overall upward trajectory of the medtech industry [1], [2].
“Stryker stock looks undervalued with a 13% discount to fair value”
The discrepancy between Stryker's operational performance—marked by raised profit forecasts—and its current stock price suggests that the market may not yet have fully priced in the company's growth trajectory. When combined with massive industry consolidation, such as the $21 billion and $17.5 billion deals seen in the sector, it indicates a period of aggressive scaling and portfolio optimization across the global medical technology landscape.
